Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer
Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National Institute for Health and Care Excellence (NICE). The negative recommendation means Zytiga won’t be made routinely available for men with newly diagnosed metastatic prostate cancer. As it is recommended now, Zytiga will only be prescribed through the NHS for these men once standard hormone treatment or chemotherapy has failed. In two recent Phase 3 trials – STAMPEDE and LATITUDE – first-line therapy with Zytiga along with steroids and hormone therapy was found to reduce the chance of cancer recurrence and improve survival, compared to hormone therapy alone. STAMPEDE (
Subscribe or to access all post and page content.